Nicola Normanno

Address INT-Fondazione Pascale
Naples
Country

Italy

Nicola Normanno

Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology.

Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department.

Since 1993 Dr Normanno’s area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumours; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; identification of markers of response or resistance to anti-EGFR agents.

Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and President Elect of the Italian Cancer Society (SIC).

Dr Normanno is a reviewer for several peer reviewed journals among which: Annals of Oncology, Breast Cancer Research and Treatment, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Associate Editor of BMC Cancer and Gene.

Dr Normanno is the author of over 200 papers published in peer reviewed journals with an H Index of 63.